Results 81 to 90 of about 1,227,712 (209)

2008 Progress Report on Brain Research [PDF]

open access: yes, 2008
Highlights new research on various disorders, nervous system injuries, neuroethics, neuroimmunology, pain, sense and body function, stem cells and neurogenesis, and thought and memory.
Eve Marder   +3 more
core  

Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control Study of the ALSPAC Longitudinal Birth Cohort [PDF]

open access: bronze, 2017
Jane A. English   +14 more
openalex   +1 more source

Alterations in blood proteins in the prodromal stage of bipolar II disorders [PDF]

open access: gold, 2022
Hyunju Lee   +18 more
openalex   +1 more source

Genetic Disease Burden, Nutrition and Determinants of Tribal Health Care in Chhattisgarh State of Central-East India: A Status Paper [PDF]

open access: yes, 2011
Tribal health is an important aspect of development and progress of the people. This study pertaining to genetic disease burden, nutritional status and biomedical anthropological assessment with particular reference to determinants of tribal health care ...
Balgir, RS
core   +1 more source

Influence the Baths of Bishophite on Indicators of Protein S100B in Blood in Children with Autistic Spectrum Disorders

open access: diamond, 2020
Т Ф Голубова   +4 more
openalex   +1 more source

Identification of candidate nsSNPs of the human FNDC5 gene and their structural and functional consequences using in silico analysis

open access: yesScientific Reports
Fibronectin type-III domain containing protein-5 (FNDC5), predominantly expressed in skeletal muscles, encodes FNDC5 transmembrane-protein. A segment of this protein is cleaved and secreted into blood as irisin, which promotes browning of white adipose ...
Sadaf Majeed   +5 more
doaj   +1 more source

Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. [PDF]

open access: yes, 2020
BackgroundThe purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-implemented language intervention (
Abbeduto, Leonard   +10 more
core  

Home - About - Disclaimer - Privacy